Merck to buy biopharmaceutical firm VelosBio for $2.75bn

This article was originally published here

Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate

The post Merck to buy biopharmaceutical firm VelosBio for $2.75bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply